Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests

被引：0

作者：

Schattenberg, Joern ^{[1
]}

Gronbaek, Henning ^{[2
]}

Kliers, Iris ^{[3
]}

Ladelund, Steen ^{[3
]}

Long, Michelle ^{[3
]}

Nygard, Sune Boris ^{[3
]}

Sanyal, Arun ^{[4
]}

Davies, Melanie ^{[5
,6
]}

机构：

[1] Univ Med Ctr Mainz, Metab Liver Res Program, Mainz, Germany

[2] Aarhus Univ Hosp, Dept Gastroenterol & Hepatol, Aarhus, Denmark

[3] Novo Nordisk, Soborg, Denmark

[4] Virginia Commonwealth Univ, Sch Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA

[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England

[6] NIHR Leicester Biomed Res Ctr, Leicester, Leics, England

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

FRI-469

引用

页码：S811 / S812

页数：2

共 50 条

[21] The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients
Smits, Mark M.
Tonneijck, Lennart
Muskiet, Marcel H. A.
Hoekstra, Trynke
Kramer, Mark H. H.
Diamant, Michaela
van Raalte, Daniel H.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 124 : 1 - 10
[22] Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
Hoda Taheri
Mojtaba Malek
Faramarz Ismail-Beigi
Farhad Zamani
Masoudreza Sohrabi
Mohammad Reza babaei
Mohammad E. Khamseh
Advances in Therapy, 2020, 37 : 4697 - 4708
[23] Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
Taheri, Hoda
Malek, Mojtaba
Ismail-Beigi, Faramarz
Zamani, Farhad
Sohrabi, Masoudreza
Reza Babaei, Mohammad
Khamseh, Mohammad E.
ADVANCES IN THERAPY, 2020, 37 (11) : 4697 - 4708
[24] Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: A randomized, placebo-controlled trial
Leite, Nathalie C.
Viegas, Bianca B.
Villela-Nogueira, Cristiane A.
Carlos, Fernanda O.
Cardoso, Claudia R. L.
Salles, Gil F.
DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1266 - 1270
[25] EFFECTS OF ORAL HIGH-DOSE VITAMIN D SUPPLEMENTATION ON NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Barchetta, I.
Angelico, F.
Del Ben, M.
Di Martino, M.
Fraioli, A.
La Torre, G.
Morini, S.
Tiberti, C.
Del Vescovo, R.
Bertoccini, L.
Cimini, F. A.
Catalano, C.
Baroni, M. G.
Cavallo, M. G.
JOURNAL OF HEPATOLOGY, 2016, 64 : S483 - S483
[26] Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with Type 2 diabetes: pooled data from four randomised, placebo-controlled phase III trials
Hach, T.
Gerich, J.
Salsali, A.
Kim, G.
Hantel, S.
Woerle, H. J.
Broedl, U. C.
DIABETIC MEDICINE, 2014, 31 : 64 - 65
[27] Urinary tract infections and genital infections in patients with Type 2 diabetes treated with empagliflozin: pooled data from four randomised, placebo-controlled phase III trials
Kim, G.
Gerich, J.
Salsali, A.
Hach, T.
Hantel, S.
Woerle, H. J.
Broedl, U. C.
DIABETIC MEDICINE, 2014, 31 : 65 - 65
[28] Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
Newsome, Philip N.
Bugianesi, Elisabetta
Ratziu, Vlad
Rinella, Mary E.
Roden, Michael
Engebretsen, Kristiane A.
Kliers, Iris
Ostergaard, Laura
Vanni, Denise
Zacho, Jeppe
Sanyal, Arun J.
JOURNAL OF HEPATOLOGY, 2024, 80 : S606 - S607
[29] Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
George, Jacob
Newsome, Philip N.
Bugianesi, Elisabetta
Ratziu, Vlad
Rinella, Mary E.
Roden, Michael
Engebretsen, Kristiane A.
Kliers, Iris
Ostergaard, Laura
Vanni, Denise
Zacho, Jeppe
Sanyal, Arun J.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 72 - 73
[30] Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
Hu, Changlun
Qu, Tianhua
Li, Lin
Huang, Yi
Liu, Huabao
Rao, Chunyan
AFRICAN HEALTH SCIENCES, 2023, 23 (02) : 416 - 421

← 1 2 3 4 5 →